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Antibodies protect against homologous Dengue
virus (DENV) infection but can precipitate severe
dengue by promoting heterotypic virus entry via
Fcg receptors (FcgR). We immortalized memory B
cells from individuals after primary or secondary
infection and analyzed anti-DENV monoclonal anti-
bodies (mAbs) thus generated. MAbs to envelope
(E) protein domain III (DIII) were either serotype
specific or cross-reactive and potently neutralized
DENV infection. DI/DII- or viral membrane protein
prM-reactive mAbs neutralized poorly and showed
broad cross-reactivity with the four DENV serotypes.
All mAbs enhanced infection at subneutralizing
concentrations. Three mAbs targeting distinct
epitopes on the four DENV serotypes and engineered
to prevent FcgR binding did not enhance infection
and neutralized DENV in vitro and in vivo as postex-
posure therapy in a mouse model of lethal DENV
infection. Our findings reveal an unexpected degree
of cross-reactivity in human antibodies against
DENV and illustrate the potential for an antibody-
based therapy to control severe dengue.
INTRODUCTION
Dengue virus (DENV) is a mosquito-borne Flavivirus responsible
for tens of millions of human cases of dengue annually, including
500,000 hospitalizations and 20,000 deaths (Gibbons and
Vaughn, 2002), with an economic burden rivaling that of malaria.Cell Host &A primary infection is believed to provide effective, durable, and
possibly life-long protection against reinfection with the same
serotype but only short-term protection against other serotypes
(Rothman, 2004). Classical epidemiologic studies suggested
that immunity to one of the four DENV serotypes can increase
disease severity upon subsequent challenge with a different
serotype, leading, in some cases, to severe dengue, a disease
characterized by plasma leakage and hemorrhagic manifesta-
tions (Halstead, 1970). Poorly neutralizing cross-reactive anti-
bodies raised in response to a previous serotype are believed
to contribute to pathogenesis of severe dengue by promoting
virus entry via Fcg receptors (FcgR) and infection ofmyeloid cells
(Halstead, 2003), leading to antibody-dependent enhancement
(ADE) of infection. The role of antibodies in severe dengue is
supported by epidemiological studies showing that infants with
waning levels of maternal antibodies (age 6–9 months) are
most vulnerable to severe DENV disease (Halstead et al., 2002;
Nguyen et al., 2004) and that serum from these infants enhances
DENV infection in vitro (Chau et al., 2008; Kliks et al., 1988). The
difficulty of balancing immunity to the four serotypes and mini-
mizing incomplete response and the risk of ADE are major
hurdles in the development of a tetravalent vaccine against
DENV (Whitehead et al., 2007).
The 10.7 Kb RNA genome of DENV encodes three structural
proteins, the capsid protein (C), a membrane-associated protein
(prM), and an envelope protein (E), and seven nonstructural
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The
E protein is structurally conserved among flaviviruses and
consists of three distinct domains. Domain I (DI) participates in
the conformational changes required for viral entry and nucleo-
capsid escape from the endosomal compartment, domain II
(DII) contains the fusion loop, and domain III (DIII) has been sug-
gested to bind cellular receptors (Bhardwaj et al., 2001; Chin
et al., 2007; Chu et al., 2005; Rey et al., 1995). Partially matureMicrobe 8, 271–283, September 16, 2010 ª2010 Elsevier Inc. 271
Table 1. DENV-Immune Donors and B Cell Repertoire Analysis
Infecting Serotype Time p.i.
Immortalization
Efficiency Primary Screening
Positive
Cultures/Total
DENV- or E-Reactive
B Cells (%)a
Donor 7 primary DENV-4 200 days 9.1% ELISA E4 protein 81/2844 1.5%
Donor 13b primary DENV-2 > 8 years 6.5% staining of infected
C6/36 cellsc
567/2016 10.7%
ELISA E2 protein 152/2016 2.9%
Donor 76 primary DENV-3 241 days 14% staining of infected
C6/36 cellsd
434/960 16%
Donor 12e secondary DENV-1 510 days 13.8% staining of infected
C6/36 cellsd
245/1632 5.4%
12.7% ELISA E1 protein 313/13824 3.2%
Donor 92 secondary DENV-2 212 days 9% ELISA DENV lysates 344/2208 8.6%
PBMCwere obtained from four donors after a primary or secondary DENV infection and frozen until the day of use. Shown is the infecting serotype and
the days postinfection (p.i.) when blood was collected. IgG+ memory B cells were immortalized with EVB and CpG. Also shown is the efficiency of
immortalization and the number and fraction of cultures containing antibodies against DENV identified using different screening methods.
a Frequency of DENV- or E-reactive IgG+ B cells was calculated from the number of positive cultures and the number of input cells per well after
correction for the efficiency of B cell immortalization.
b Supernatants were tested using two different screening assays.
c C6/36 cells were infected with DENV-2, WHO reference strain 516803.
dC6/36 cells were infected with DENV isolated from the same donor.
e Two independent immortalizations were performed.
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Cross-Reactive Human mAbs to Dengue Virusvirions also express varying levels of prM protein on their
surface, which is normally cleaved by a furin-like cellular
protease to generate the mature virion (Stadler et al., 1997).
The most potent neutralizing antibodies against DENV, or
other flaviviruses such as West Nile Virus (WNV), bind to DIII
and have been shown in some cases to be effective as passive
prophylaxis or therapy in rodents (Beasley and Barrett, 2002;
Goncalvez et al., 2008; Gromowski et al., 2008; Kaufman et al.,
1987; Oliphant et al., 2005; Sa´nchez et al., 2005; Shrestha
et al., 2010; Sukupolvi-Petty et al., 2007). DIII-reactive antibodies
produced by mice immunized with virus and boosted with
recombinant E protein are largely serotype-specific and do not
neutralize all of the genotypes within a given serotype (Shrestha
et al., 2010). The role of antibodies to DI/DII is less clear, as they
tend to be more cross-reactive and less potent in neutralization
(Crill and Chang, 2004; Goncalvez et al., 2004; Oliphant et al.,
2006). Antibodies to prM generally have poor neutralizing and
enhancing activity (Falconar, 1999; Huang et al., 2006), although
recent studies suggest that some anti-prM mAbs can augment
infectivity of poorly infectious immature virions (Rodenhuis-
Zybert et al., 2010). Antibodies against NS1, a secreted
nonstructural glycoprotein that is absent from the virion but
expressed on the cell surface, can also protect against infection
in vivo through FcgR-dependent and -independent mechanisms
(Chung et al., 2006) or can possibly contribute to pathogenesis
(Falconar, 2007; Lin et al., 2008).
Our current knowledge of the human antibody response to
DENV is mostly based on serological studies. In this study, we
used an improved method of memory B cell immortalization
(Traggiai et al., 2004) combinedwith a broad screening approach
to isolate a large panel of DENV-reactive mAbs from human
donors. MAbs that bound to DIII of the E protein potently neutral-
ized DENV infection, although they also showed enhancing
activity at lower concentrations. In contrast, mAbs that bound
to DI/DII of E protein or prM neutralized poorly yet potently272 Cell Host & Microbe 8, 271–283, September 16, 2010 ª2010 Elsenhanced infection of FcgR-bearing cells. Surprisingly, some
of the human DIII-specific mAbs and all DI/DII-specific mAbs
isolated from secondary infection showed a broad pattern of
cross-reactivity with the four DENV serotypes. Based on an
improved understanding of the functional humoral response
against DENV, we produced a cocktail of three variant recombi-
nant mAbs that neutralized all four DENV serotypes without
causing immune enhancement in vitro and in vivo.
RESULTS
High Frequency of DENV-Specific Memory B Cells
in Immune Donors
Blood samples were collected from donors at different time
points after diagnosis of either primary (donor 7, donor 13, and
donor 76) or secondary (donor 12 and donor 92) DENV infection.
IgG+ memory B cells isolated from frozen PBMC were immortal-
ized with EBV and CpG in multiple replicate wells as previously
described (Traggiai et al., 2004). Culture supernatants were
collected after 2 weeks and analyzed by staining of fixed
and permeabilized C6/36 mosquito cells infected with DENV or
by ELISA using recombinant E protein from DENV-1, DENV-2,
and DENV-4 or lysates of DENV-infected cells (Table 1). The
frequency of IgG+ memory B cells reactive against DENV-
infected cells, calculated from the number of positive cultures
and the number of input cells after corrections for the efficiency
of B cell immortalization, was high in all donors, ranging from
5.4% to 16% of IgG+ memory B cells. In the three donors that
were screened using E protein, the frequency of E-reactive
IgG+ memory B cells ranged from 1.5% to 3.2%. These findings
indicate that DENV-immune donors maintain a very large pool of
memory B cells reactive against DENV proteins, even several
years after infection.
Because the E protein, and in particular DIII, is the main target
of neutralizing anti-WNV antibodies in mice (Oliphant et al.,evier Inc.
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domain specificity and cross-reactivity of E-specific antibodies
isolated from donor 13 (primary DENV-2) and donor 12
(secondary DENV-1). Eighteen out of 152 antibodies from donor
13 bound to DIII of DENV-2. Of these, 13 were serotype specific,
1 cross-reacted with DENV-2, -3, and -4, and 4 cross-reacted
with all four DENV serotypes. In the case of donor 12, a large
fraction of E-reactive antibodies bound to DIII (138 out of 313).
Of these, 44 were specific for DIII of DENV-1, whereas the
remaining 94 were cross-reactive with two, three, or all four
DENV serotypes (16, 15, and 63, respectively). Taken together,
these findings indicate that the human antibody response to
DIII of DENV E protein elicited by natural infection comprises
serotype-specific as well as broadly cross-reactive antibodies.Isolation of Human Monoclonal Antibodies to DENV
In order to better characterize the human antibody response to
DENV, we isolated B cell clones from several independent
cultures and characterized 70 DENV-reactive monoclonal
antibodies (mAbs) (68 IgG1, either k or l, 1 IgG3, l, and
1 IgG4, l). All DENV-reactive mAbs bound to one or more
DENV serotypes, as shown by staining of Vero cells infected
with DENV-1, DENV-2, DENV-3, or DENV-4 (see examples in
Figure 1A). Specificity and cross-reactivity were assessed using
binding assays (ELISA with recombinant E, NS1, and NS3
proteins, staining of yeast displaying DI/DII or DIII, or western
blot of infected cell lysates) (see examples in Figures 1B–1D).
Mabs were also characterized using functional assays (neutrali-
zation or enhancement of infection by DENV vaccine strains
using flow cytometry assays with Vero and K562 cells, respec-
tively; Kraus et al., 2007; Littaua et al., 1990) (see examples in
Figures 1E and 1F).Serotype-Specific and Cross-Reactive mAbs
to DIII of E Protein
Of the 70 DENV-reactive mAbs isolated, 13 mapped to DIII of E
protein, and of these, 5 were serotype specific, whereas 8 were
cross-reactive with two, three, or even all four DENV serotypes
(Table 2). Of the five serotype-specific mAbs, three (DV3.7,
DV25.5, and DV470.12) potently neutralized infection of Vero
cells by either DENV-1 or DENV-2 vaccine strains, with EC50
values in the low ng/ml range, whereas two mAbs (DV1.6 and
DV14.5) showed decreased potency against DENV-2, suggest-
ing that they may represent low-affinity antibodies or may target
private epitopes within DENV-2. Of the eight cross-reactive
mAbs, two (DV63.1 and DV55.1) potently neutralized DENV-1
and DENV-3, whereas mAb DV87.1 potently neutralized
DENV-1, DENV-2, and DENV-3. Strikingly, the cross-reactive
mAbs DV63.1 and DV87.1 neutralized infection in the same
range of concentrations as observed for serotype-specific
mAbs (Table 2). Finally, four mAbs bound all serotypes by ELISA,
and of these, two neutralized, albeit with low potency, all sero-
types (DV21.5 and DV257.13), whereas the remaining mAbs
showed a more restricted pattern of neutralization.
Consistent with what is known about the stoichiometric rela-
tionship between neutralization and enhancement (Pierson
et al., 2007), DIII-specific mAbs also enhanced infection of
K562 cells over a given range of concentrations with theCell Host &same serotype specificity as shown in the neutralization assay
(Table 2).
These results indicate that it is possible to isolate DIII-reactive
human mAbs that potently neutralize infection of two or more
DENV serotypes.
DI/DII-Specific mAbs from Secondary DENV Infection
Cross-React with All Four DENV Serotypes
Of the 70 DENV-reactive mAbs, 34 mapped to DI/DII of E protein
(Table 3). Of these, 8 were serotype-specific, 1 cross-reacted
with DENV-1 and DENV-2, and 25 cross-reacted with all four
DENV serotypes. When compared to DIII-specific mAbs, the
DI/DII-specific mAbs showed in general a 10- to 50-fold lower
potency of neutralization and enhanced infection over a wide
range of concentrations (Table 3). Of interest, whereas DI/DII-
reactive mAbs isolated from primary infections (donors 7, 13,
and 76) were mostly serotype specific, all DI/DII-reactive mAbs
isolated from secondary infection (donors 12 and 92) neutralized
and enhanced infection by all four DENV serotypes. These find-
ings suggest that broadly cross-reactive DI/DII-specific memory
B cells may be selected during the course of secondary DENV
infection.
Some of the broadly reactive DI/DII-specific mAbs were
analyzed for reactivity against West Nile virus (WNV). Seven
mAbs stained yeast cells expressing DI/DII of WNV E protein
(Table S1 available online). Using site-directed mutants in DII
that had been previously generated (Crill and Chang, 2004;
Oliphant et al., 2006), we localized binding of three mAbs to
the fusion loop peptide at the tip of DII (W101R, G106E) and of
a fourth mAb to the W233F residue on the dimmer interface of
DII. The binding of the other three cross-reactive mAbs was
not affected by these mutations, indicating that they map to
DI/DII but outside of the fusion loop region.
Finally, 4 mAbs (DV66.1, DV57.4, DV61.2, and DV77.5), which
were selected for binding to DENV-infected cells, did not bind
to recombinant E proteins in ELISA but bound to E protein
in western blot (Figure 1B). DV66.1 and DV57.4 neutralized
one and three DENV serotypes, respectively, whereas DV61.2
and DV77.5 did not neutralize DENV infection at the highest
concentration tested. However, all 4 mAbs showed ADE activity
(Table 3).
Human Monoclonal Antibodies to prM
and to Nonstructural Proteins
We next characterized 19 mAbs that stained DENV-infected
cells but did not recognize E protein. Six mAbs reacted with
a band in western blot corresponding to prM, as indicated by
the mouse anti-prM mAb 2H2 used as control (Falconar, 1999)
(Figure 1C). As independent verification, we also performed
cross-competition experiments and found that the anti-prM
mAbs DV64.3, DV27.2, and DV69.6 inhibited binding of 2H2,
suggesting that they may recognize the same or overlapping
epitopes, whereas DV52.1, DV75.9, andDV62.5 did not compete
with 2H2 and may recognize distinct epitopes (data not shown).
Surprisingly, five of thesemAbs stained a band corresponding to
E-prM protein, and three of them (DV64.3, DV52.1, and DV62.5)
also recognized a band corresponding to the E protein. The reac-
tivity of mAbs with both prM and E suggests a quaternary
epitope with shared sites on the heterodimeric prM-E protein;Microbe 8, 271–283, September 16, 2010 ª2010 Elsevier Inc. 273
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Figure 1. Specificity and Function of Human mAbs against DENV
(A) Vero cells, uninfected or infected by DENV-1, -2, -3, and -4 vaccine strains, were fixed, permeabilized, and stained with human mAbs, followed by fluores-
cently labeled anti-human IgG polyclonal antibodies. Representative dot plots show staining by mAbs isolated from donor 76 reactive against DENV-3 alone
(mAb DV79.3), DENV-1 and DENV-3 (mAb DV63.1), or cross-reactive against the four DENV serotypes (mAbs DV82.11, DV69.6, DV59.3). Numbers in quadrants
indicate the percentage of positive cells. The data shown are for five mAbs and are representative of data obtained with 70 DENV-reactive mAbs and of at least
two independent experiments.
(B–D) Western blot analysis of mAbs that were not reactive by ELISA. Concentrated supernatants of uninfected control (–) or DENV-3-infected Vero cells (+) were
separated under nonreducing conditions. (B) E- and capsid-specific mAbs. E protein was identified by DV55.1, a mAb specific for E protein in ELISA. Capsids
migrate with apparent molecular weights of 16 kD. (C) prM-specific mAbs. PrM protein was identified by the mouse anti-prM mAb 2H2. (D) NS1-specific mAbs.
NS1 protein was identified by a rabbit anti-NS1 serum. The data are representative of at least two independent experiments.
(E) Examples of viral neutralization assay inwhich serial dilutions ofmAbs (DV63.1 andDV5.1) were incubated with DENV-1–4 before addition to Vero cells. Shown
is the percentage of infected cells after 3 days as a function of increasingmAb concentration. Nonlinear regression analysis was used to calculate the EC50 values
indicated in the panel.
(F) Infection enhancement assay in which serial mAb dilutions were incubated with DENV-1–4 before addition to K562 cells. Shown is the percentage of infected
K562 cells. The range of mAb concentrations where infection enhancement was observed is indicated in gray. Numbers in the gray areas represent logarithm
power. The data shown are from one representative experiment out of three independent experiments performed. Data obtained with the panel of DENV-reactive
mAbs are shown in Tables 2, 3, and 4.
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Cross-Reactive Human mAbs to Dengue Virusa similar finding has been reported for mouse antibodies
(Falconar, 1999; Gould et al., 1985; Puttikhunt et al., 2008).
With the single exception of mAb DV52.1, all of the prM-specific
mAbs were broadly cross-reactive, as they bound to cells274 Cell Host & Microbe 8, 271–283, September 16, 2010 ª2010 Elsinfected with all four DENV serotypes (Table 4). All prM-reactive
mAbs enhanced DENV infection over a broad range of concen-
trations, whereas only three neutralized infection with low
potency (Table 4). Thus, consistent with a recent studyevier Inc.
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l).t &(Dejnirattisai et al., 2010), the prM-specific mAbs were highly
cross-reactive among the DENV serotypes and potently
promoted ADE.
ElevenmAbs weremapped to NS1 or NS3 protein, as deter-
mined by ELISA with recombinant proteins and western blot
(Figure 1D and data not shown). Five NS1-specific mAbs
cross-reacted with all DENV serotypes, whereas the remaining
two mAbs reacted with DENV-1 and DENV-3, and the four
NS3-specific mAbs were all DENV-3-specific (Table 4). Finally,
only one mAb (DV86.2) recognized the capsid protein (Table 4
and Figure 1B). Another mAb (DV34.4) was not assigned to
a specific protein, although it showed high neutralizing activity
against DENV-2 and, to a lower extent, DENV-4 (Table 4). This
mAb likely recognizes a conformationally sensitive epitope
on E (e.g., hinge or interface between domains of oligomers),
as was observed recently with two human mAbs against WNV
(Vogt et al., 2009).
A Broadly Neutralizing Antibody Cocktail Lacking
Enhancing Activity
Given the availability of human mAbs that potently neutralized
DENV infection, we set out to develop a candidate antibody-
based therapeutic for dengue consisting of a ‘‘cocktail’’ of
neutralizing mAbs. Ideally, this cocktail should: (1) neutralize all
DENV serotypes, (2) target at least two nonoverlapping epitopes
on each virus in order to minimize selection of escape mutants,
and (3) fail to enhance infection. We therefore selected two
mAbs with potent and complementary neutralizing activity:
DV87.1 specific for DIII of DENV-1, -2, and -3 and DV22.3
specific for DI/DII of DENV-4. As a complement, we selected
a DI/DII-specific mAb (DV82.11) that neutralized with compa-
rable efficiency all four DENV serotypes (Figure 2A). Cross-
competition experiments were consistent with the notion that
the target epitopes recognized by the threemAbs did not overlap
(Figure S1). Thus, a cocktail of DV87.1, DV22.3, and DV82.11 is
expected to neutralize all DENV serotypes by targeting two
distinct sites on each virus.
Because the selected neutralizing mAbs also enhanced infec-
tion (Figure 2A), we generated variants of DV87.1, DV22.3, and
DV82.11 in which leucine residues at positions 1.3 and 1.2 of
CH2 domain (according to the IMGT unique numbering for
C domain) were substituted with alanine residues. This modifica-
tion, also known as ‘‘LALA’’ mutation, abolishes antibody
binding to FcgRI, FcgRII, and FcgRIIIa (Hessell et al., 2007).
The variant and unmodified recombinant mAbs were expressed
in HEK293T cells, and the purifiedmAbs were compared for their
capacity to neutralize and enhance infection by the four DENV
serotypes. As shown in Figure 2B, LALA variants retained the
same neutralizing activity as unmodified mAbs but were
completely devoid of enhancing activity. In addition, the LALA
cocktail, even at very low concentrations (DV82.11 = 2 mg/ml;
DV87.1 = DV22.3 = 0.2 mg/ml), blocked ADE induced by
enhancing prM or DI/DII mAbs or immune serum (Figure 2C).
To determine whether the combination of LALA mAbs might
achieve increased neutralization, we used a variable ratio
approach (Zwick et al., 2001). The concentration of one mAb
was varied in the presence of a fixed amount of a second mAb
(added at a weakly neutralizing concentration), and the titration
curves of the first mAb alone or in combination were compared.Microbe 8, 271–283, September 16, 2010 ª2010 Elsevier Inc. 275
Table 3. Characterization of DI/DII E-Reactive Human mAbs
ELISA E Protein Yeasts DV2 Neutralization (EC50 mg/ml) Range of Enhancement (log10 mg/ml)
mAbs Donor Isotype Specificity DV 1 DV 2 DV 3 DV 4 DIII DV 3/4 DI/DII DIII DV 1 DV 2 DV 3 DV 4 DV 1 DV 2 DV 3 DV 4
DV 13.8 Don 13 g1, l E, DI/DII — + — — — n.d. — — 0.241 — — — 2, 1 — —
DV 16.8 Don 7 g1, k E, DI/DII — — — + — n.d. — — — — 0.039 — — — 2, 0
DV 18.21 Don 13 g1, k E, DI/DII — + — — — n.d. — — 0.003 — — — 3, 0 — —
DV 22.3 Don 7 g1, l E, DI/DII — — — + — n.d. — — — — 0.006 — — — 2, 1
DV 35.3 Don 13 g1, k E, DI/DII — + — — — n.d. — — 0.918 — — — 1, 1 — —
DV 74.4 Don 76 g1, l E, DI/DII — — + — — n.d. — — — 0.020 — — — 2,0 —
DV 79.3 Don 76 g1, k E, DI/DII — — + — — n.d. — — — 0.023 — — — 2, 0 —
DV 76.5 Don 76 g1, k E, DI/DII — — + — — n.d. — — — — — 1, 2 2, 1 2, 1 2, 1
DV 90.3 Don 76 g1, l E, DI/DII + — + — — n.d. — 0.342 — 0.454 — 2, 1 — 1, 1 —
DV 1.1 Don 92 g1, l E, DI/DII + + + + — + — 0.209 0.066 0.262 0.183 2, 1 2, 1 2, 1 2, 1
DV 4.4 Don 92 g1, l E, DI/DII + + + + — + — 0.248 0.214 0.167 0.760 2, 1 2, 1 1, 1 2, 1
DV 5.1 Don 92 g1, k E, DI/DII + + + + — + — 0.156 0.103 0.092 0.069 2, 1 2, 1 2, 1 3, 1
DV 6.1 Don 92 g1, l E, DI/DII + + + + — + — 0.382 0.296 0.351 0.170 1, 1 2, 1 1, 1 2, 1
DV 7.5 Don 92 g1, k E, DI/DII + + + + — + — 0.084 0.075 0.130 0.031 2, 1 2, 1 2, 1 2, 1
DV 8.1 Don 92 g1, l E, DI/DII + + + + — + — 0.103 0.022 0.031 0.024 3, 2 2, 1 3, 1 3, 0
DV 13.4 Don 92 g1, l E, DI/DII + + + + — + — 0.063 0.023 0.016 0.045 2, 1 3, 0 3, 0 3, 0
DV 14.5 Don 92 g1, l E, DI/DII + + + + — + — 0.053 0.049 0.060 0.040 2, 0 2, 0 2, 0 3, 0
DV 15.7 Don 92 g1, l E, DI/DII + + + + — + — 0.123 0.055 0.173 0.070 2, 1 3, 1 2, 1 3, 1
DV 16.5 Don 92 g1, k E, DI/DII + + + + — + — 0.248 0.089 0.219 0.101 2, 1 2, 1 2, 1 2, 1
DV 17.6 Don 92 g1, l E, DI/DII + + + + — + — 0.218 0.103 0.256 0.087 2, 1 2, 1 2, 1 2, 2
DV 18.4 Don 92 g1, k E, DI/DII + + + + — + — 0.670 0.241 0.799 0.699 2, 1 2, 1 2, 1 2, 1
DV 19.3 Don 92 g1, k E, DI/DII + + + + — + — 0.631 0.189 0.368 0.114 2, 1 2, 1 2, 1 2, 1
DV 20.1 Don 92 g1, l E, DI/DII + + + + — + — 0.244 0.128 0.777 0.226 2, 1 2, 1 1, 1 2, 1
DV 21.1 Don 92 g1, k E, DI/DII + + + + — + — 0.161 0.055 0.069 0.101 2, 1 2, 1 3, 1 3, 1
DV 23.13 Don 13 g1, l E, DI/DII + + + + — n.d. — n.d. 0.013 n.d. n.d. n.d. 3, 1 n.d. n.d.
DV 28.1 Don 12 g1, l E, DI/DII + + + + — n.d. — 0.093 0.027 0.084 0.027 3, 1 3, 1 3, 1 3, 1
DV 28.8 Don 92 g1, k E, DI/DII + + + + — + — 0.106 0.048 0.233 0.092 2, 0 2, 0 2, 0 2, 1
DV 38.1 Don 92 g1, l E, DI/DII + + + + — + — 0.111 0.036 0.239 0.106 2, 1 3, 1 2, 1 3, 1
DV 78.6 Don 76 g1, k E, DI/DII + + + + — n.d. — 0.591 0.251 0.809 0.367 2, 1 2, 1 2, 1 2, 1
DV 82.11 Don 76 g1, l E, DI/DII + + + + — n.d. — 0.043 0.024 0.090 0.117 2, 1 2, 1 2, 1 2, 1
DV 143.6 Don 12 g1,k E, DI/DII + + + + — n.d. — 0.253 0.083 0.255 0.070 2, 1 2, 1 2, 1 n.d.
DV 163.3 Don 12 g1,k E, DI/DII + + + + — n.d. — 0.170 0.100 0.187 0.542 2, 1 2, 0 1, 0 n.d.
DV 378.12 Don 12 g1,k E, DI/DII + + + + — n.d. — 0.149 0.072 0.251 0.498 2, 1 2, 1 3, 1 n.d.
DV 291.3 Don 12 g1, l E, DI/DII + + + + — n.d. — 0.120 0.080 0.199 0.202 2, 0 2, 1 2, 1 n.d.
DV 66.1 Don 76 g1, k E — — — — — n.d. — — — 1.950 — — — 2, 1 —
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Cell Host & Microbe
Cross-Reactive Human mAbs to Dengue Virus
Cell Host &The EC90 values shown in Table S2 indicate a 2- to 4-fold
increase in neutralization potency, consistent with a modest
additive effect.
Taken together, the above results suggest that a cocktail of
three LALA variant mAbs targeting different epitopes on each
virus can efficiently neutralize DENV infection while avoiding
and actually preventing enhancement of DENV infection in vitro.
LALA Variant mAbs Do Not Enhance DENV Infection
and Show Therapeutic Efficacy In Vivo
To assess the ability of LALA variants to neutralize DENV in vivo,
we utilized a recently described mouse model of DENV ADE in
which sublethal infection is enhanced by passive transfer of
anti-DENV antibodies, leading to lethal disease characterized
by plasma leakage, elevated serum cytokines, and thrombocy-
topenia (Balsitis et al., 2010; Zellweger et al., 2010), all features
associated with severe dengue in humans. Unmodified or
LALA variant mAbs were transferred into AG129 mice 24 hr
prior to a sublethal infection with DENV-2 strain D2S10.
Whereas mice receiving 5 mg of the mouse mAb 4G2 (pan-flavi-
virus, E DI/DII specific) developed an enhanced, lethal D2S10
infection, mice receiving 1 or 5 mg of LALA mAb variants did
not succumb to infection (Figure 3A; 1 or 5 mg DV87.1 LALA,
p < 0.0253; 1 or 5 mg DV82.11 LALA, p < 0.0455 as compared
to 5 mg 4G2) or show signs of illness. In contrast, with one excep-
tion, all of the mice pretreated with 1 or 5 mg unmodified mAbs
DV87.1 and DV82.11 showed enhanced lethal DENV infection,
whereas five of six mice receiving PBS alone survived infection
(Figure 3A). The ability of the unmodified mAbs to enhance
DENV in mice was not affected by differences in the interaction
between the human mAbs and the murine Fcg. Indeed, chimeric
mAbs in which the human constant region (hinge, CH2 and CH3
domains) was replaced with the homologous murine Igg2a
constant region enhanced DENV infection comparably in vitro
and in vivo (data not shown).
To determine whether survival associated with transfer of
the DV87.1 and DV82.11 LALA variants was associated with
reduced viral load, we measured the viral burden in serum and
tissues 3.5 days following D2S10 antibody-enhanced infection.
Viremia and tissue viral load measured in liver, small intestine,
and lymph node were significantly decreased in mice receiving
5 mg of either LALA variant as compared to mice receiving 5 mg
of the parent unmodified mAbs (Figure S2, p < 0.0495 for
comparisons betweenmAb variants in the liver, sera, and lymph;
in the small intestine, p < 0.0369 for comparison between
DV87.1 mAb variants and p < 0.0463 between DV82.11 mAb
variants).
To explore whether the LALA variants could serve as a
possible therapy following DENV infection, we administered
50 mg of the LALA variants or unmodified mAbs to mice 24 hr
after infection with DENV-2 D2S10 under enhancing conditions
(24 hr after transfer of heterotypic anti-DENV-1 serum) (Balsitis
et al., 2010). Mice receiving either the DV87.1 or DV82.11 LALA
variant survived the normally lethal infection, whereas mice
receiving the unmodified parent mAbs succumbed to infection,
as did mice receiving a nonbinding isotype control (DV22.3
LALA mAb that only recognizes DENV-4) or PBS (Figure 3B,
DV87.1 LALA, p < 0.0015; DV82.11 LALA, p < 0.011 compared
to DV22.3 LALA). In summary, engineering of the LALA mutationMicrobe 8, 271–283, September 16, 2010 ª2010 Elsevier Inc. 277
Table 4. Characterization of Non-E-Reactive mAbs
Staining of Vero-Infected Cells Neutralization (EC50 mg/ml)
Range of Enhancement
(log10 mg/ml)
mAbs Donor Isotype Specificity DV 1 DV 2 DV 3 DV 4 DV 1 DV 2 DV 3 DV 4 DV 1 DV 2 DV 3 DV 4
DV 64.3 Don 76 g1, k prM + + + + 0.327 0.402 0.067 0.128 4, 1 4, 1 4, 1 3, 1
DV 27.2 Don 92 g1, k prM + + + + 0.391 0.345 0.110 0.076 3, 1 3, 1 3, 1 3, 1
DV 69.6 Don 76 g1, l prM + + + + 0.912 1.559 0.129 0.070 4, 1 3, 1 4, 1 4, 2
DV 52.1 Don 76 g1, k prM + — + — — — — — — — 3, 1 —
DV 75.9 Don 76 g1, k prM + + + + — — — — 2, 0 1, 2 3, 0 2, 0
DV 62.5 Don 76 g1, l prM + + + + — — — — 2, 1 2, 1 2, 1 2, 1
DV 51.6 Don 76 g1, l NS1 + — + — — — — — — — — —
DV 53.4 Don 76 g1, l NS1 + — + — — — — — — — — —
DV 54.7 Don 76 g1, k NS1 + + + + — — — — — — — —
DV 56.12 Don 76 g1, l NS1 + + + + — — — — — — — —
DV 59.3 Don 76 g4, l NS1 + + + + — — — — — — — —
DV 60.3 Don 76 g1, k NS1 + + + + — — — — — — — —
DV 70.1 Don 76 g1, k NS1 + + + + — — — — — — — —
DV 65.5 Don 76 g1, k NS3 — — + — — — — — — — — —
DV 67.9 Don 76 g1, l NS3 — — + — — — — — — — — —
DV 68.2 Don 76 g3, l NS3 — — + — — — — — — — — —
DV 71.1 Don 76 g1, l NS3 — — + — — — — — — — — —
DV 86.2 Don 76 g1, l capsid + + + + — — — — — — — —
DV 34.4 Don 92 g1, k n.a. — + — + — 0.010 — 0.431 — 3, 0 — 1, 2
The table reports the phenotype of non-E-reactive mAbs, the donor fromwhich themAbs were isolated, and the mAb isotype and light-chain usage as
determined by specific ELISA. Specificity was determined by staining of Vero cells infected with DENV and by western blot assay or ELISA. The spec-
ificity of mAb DV34.4 was not assigned (n.a.). The mAb isotype and light-chain usage were determined as described in Table 2. Viral neutralization and
enhancement assays were performed on Vero and K562 cells, respectively, using DENV-1-4 vaccine strains. Shown are EC50 values of neutralization
and range of mAb concentrations of infection enhancement. The data shown are representative of two independent experiments.
Cell Host & Microbe
Cross-Reactive Human mAbs to Dengue Viruson strongly neutralizing human mAbs abrogates the capacity for
ADE and confers a protective phenotype as a postexposure
therapy in mice.
DISCUSSION
In this study, we analyzed the memory B cell repertoires of indi-
viduals recovered fromprimary or secondary DENV infection and
characterized a large panel of mAbs specific for structural and
nonstructural proteins of DENV. The main findings are that
immune donors have a large repertoire of DENV-reactive
memory B cells, even years after infection, and that human
E-specific as well as prM-specific mAbs isolated from these
donors show extensive cross-reactivity among the four DENV
serotypes.
Previous studies usingmousemAbs established that DIII is the
primary target of the most potent neutralizing antibodies against
flaviviruses, including WNV and DENV (Beasley and Barrett,
2002; Gromowski and Barrett, 2007; Oliphant et al., 2005,
2007; Sa´nchez et al., 2005; Sukupolvi-Petty et al., 2007). Our
findings in humans agree with these observations, as the iso-
lated DIII-specific mAbs were indeed the most potent in neutral-
izing DENV infection of Vero cells, with EC50 values in the low ng/
ml range. However, whereas mAbs produced by mice boosted
with recombinant E protein could only neutralize a few geno-
types within a given serotype (Shrestha et al., 2010), the human278 Cell Host & Microbe 8, 271–283, September 16, 2010 ª2010 ElsmAbs to DIII showed considerable breadth, with some mAbs
being able to neutralize three or even all four DENV serotypes.
DI/DII-specific mAbs were less potent in viral neutralization
and showed an even higher degree of cross-reactivity. Strikingly,
analysis performed on a large number of culture supernatants
showed that the fraction of DIII and DI/DII cross-reactive anti-
bodies was considerably higher in secondary infections. For
instance 44.1% of supernatants containing DIII-specific anti-
bodies from donor 12 (secondary DENV-1) cross-reacted with
two, three, or four DENV serotypes, whereas 100% of DI/DII-
specificmAbs from donor 92 (secondary DENV-2) cross-reacted
with comparable EC50 values with all four DENV serotypes.
Within the E-specific response, the relative proportion of
DI/DII versus DIII antibodies showed considerable variability in
different donors. However, there was an overall prevalence of
DI/DII antibodies, which is consistent with serological studies
with WNV and DENV (Crill et al., 2009; Lai et al., 2008; Oliphant
et al., 2007; Wahala et al., 2009). Moreover, two recent studies
described recombinant anti-WNV antibodies that were
generated after phage display screening of scFv (VH-VL) mole-
cules (Gould et al., 2005; Throsby et al., 2006), both of which
observed immunodominance of DI/DII mAbs against WNV E
protein. For unclear reasons, it appears that DIII-specific
antibodies are less abundant in the human repertoire, although
they still may contribute significantly to protection (Crill et al.,
2009).evier Inc.
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Figure 2. Three mAbs Neutralize All Four
DENV Serotypes by Binding Two Distinct
Epitopes on Each Virus
Three mAbs (all IgG1) were selected for their
specificity and neutralizing activity: DV87.1 binds
DIII of DENV-1, -2, and -3; DV22.3 binds DI/DII of
DENV-4, and DV82.11 cross-reacts with DI/DII of
all DENV serotypes.
(A) Neutralization (B) and enhancement (C) of
infection by recombinant unmodified mAbs.
(B) Neutralization (B) and enhancement (C) of
infection by engineered LALA variant mAbs.
Nonlinear regression analysis was used to calcu-
late the EC50, indicated in the panel. Data are
mean of duplicates. One representative experi-
ment out of three performed.
(C) A cocktail of LALA-mAbs (DV82.11 = 2 mg/ml,
DV87.1 = DV22.3 = 0.2 mg/ml) was used in combi-
nation with mAbs directed against prM (DV69.6) or
DI/DII E protein (DV78.6) or serum from a primary
DENV-infected donor at potent enhancing
concentration (0.1 mg/ml) on K562 cells. Numbers
in quadrants indicate the percentage of infected
cells, as revealed by staining with an anti-E mouse
mAb. The data shown are from one experiment
representative of two performed. See also
Figure S1 and Table S2.
Cell Host & Microbe
Cross-Reactive Human mAbs to Dengue VirusAll neutralizing mAbs isolated in this study mediated ADE at
subneutralizing concentrations, whereas some E-specific
mAbs and most prM-specific mAbs mediated ADE but lacked
neutralizing activity. A previous study reported the isolation of
three human E protein-specific mAbs, two of which showed
enhancing but not neutralizing activity (Schieffelin et al., 2010).
More recently, Screaton and coworkers showed that prM-specific
mAbs represent a major component of the human DENV-specific
response and that thesemAbsare highly cross-reactive and, even
at high concentrations, do not neutralize infection but potently
promote ADE (Dejnirattisai et al., 2010). Consistent with these
data, most of the prM-specific mAbs described in the present
study were highly cross-reactive and showed ADE activity over
a broad range of concentrations. The human studies together
with previous studies on mouse anti-prM mAbs that neutralizeCell Host & Microbe 8, 271–283, Seinfection weakly, if at all, while potently
mediating ADE (Falconar, 1999; Henchal
et al., 1985; Huang et al., 2006; Men
et al., 2004; Roehrig et al., 1998) suggest
a potential role for this class of antibodies
in enhancing DENV infection in humans.
Recent studies in infants have also impli-
cated anti-prM antibodies in the suscepti-
bility of infants to severe dengue (Chau
et al., 2009). It has also been proposed
that anti-prM antibodies could enhance
DENVpropagationbyenhancing the infec-
tivity of immature, ‘‘noninfectious’’ virions
(Rodenhuis-Zybert et al., 2010). However,
because the vast majority (>99%) of
humans experiencing secondary DENV
infection do not develop severe life-threat-ening disease, the DI/DII-specific antibodies or the less frequent
highly neutralizing DIII-specific antibodies are likely protective,
along with other components of the innate and adaptive immune
system.
The development of a vaccine against DENV has been prob-
lematic, in part due to the possible risk of eliciting suboptimal
immune responses that might lead to ADE and severe disease
after infection with heterologous virulent strains. In the absence
of an effective DENV vaccine, passive immunotherapy with
neutralizing antibodies may provide an alternative for the treat-
ment of dengue. A postexposure prophylaxis approach is
currently being pursued for treatment of several viral diseases
such as respiratory syncytial virus (RSV), rabies, hepatitis B,
and WNV (Marasco and Sui, 2007). Humanized anti-DENV
mAbs obtained frommice or primates engineeredwithmutationsptember 16, 2010 ª2010 Elsevier Inc. 279
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Figure 3. LALA Variants Do Not Enhance DENV In Vivo and Demon-
strate Postexposure Therapeutic Efficacy
(A) (Top) 1 or 5 mg of DV87.1, DV87.1 LALA variant, 4G2, or PBS were trans-
ferred i.p. in 200 ml volume into AG129 mice (n = 3 per group). The mice
were infected 18–24 hr later with 106 pfu DENV-2 strain D2S10. (Bottom)
1 or 5 mg of DV82.11, DV82.11 LALA variant, 4G2, or PBS were transferred
i.p. in 200 ml volume into AG129 mice (n = 3 per group). The mice were subse-
quently infected 18–24 hr later with 106 pfu DENV-2 D2S10. All mice receiving
LALA-variant mAbs survived as compared to mice receiving a lethal, antibody-
enhanced infection (1 or 5 mg DV87.1 LALA, p < 0.0253; 1 or 5 mg DV82.11
LALA, p < 0.0455 compared to 4G2 mAb positive control).
(B) AG129 mice were administered 35 ml anti-DENV-1 serum i.p. and were
infected 24 hr later with 105 pfu of DENV-2 D2S10 i.v. At 24 hr after infection,
the mice were treated with 50 mg of either DV87.1, n = 6; DV87.1 LALA, n = 6;
DV82.11, n = 6; DV82.11 LALA, n = 5; DV22.3 LALA, n = 6; or PBS, n = 6 i.p.
In all cases, mortality was monitored daily for 10 days. Mice treated with either
50 mg DV87.1 LALA (p < 0.0015) or DV82.11 LALA (p < 0.011) 24 hr postinfec-
tion survived significantly longer thanmice receiving 50 mg of nonbinding LALA
variant mAb DV22.3.
See also Figure S2.
Cell Host & Microbe
Cross-Reactive Human mAbs to Dengue Virusthat prevent binding to FcR have been developed for this
purpose (Balsitis et al., 2010; Goncalvez et al., 2007), but fully
human mAbs generated during a natural infection represent an
attractive alternative, with a reduced antigenicity and risk of280 Cell Host & Microbe 8, 271–283, September 16, 2010 ª2010 Elsautoreactivity. Here, we selected three potent human neutral-
izing mAbs as component of a cocktail capable of targeting
two distinct epitopes on each of the four DENV serotypes and
engineered them with two leucine-to-alanine mutations in the
CH2 region that prevent binding to FcgR while preserving
binding to the neonatal FcRn (Hessell et al., 2007). The LALA
variants retained neutralizing activity and, when tested in vitro,
failed to enhance DENV infection and inhibited enhancement
elicited by polyclonal immune sera or appropriate concentra-
tions of intact antibodies. When tested in vivo in a mouse
model of lethal antibody-enhanced vascular leak syndrome,
the LALA mAbs protected against lethal infection induced by
DENV-immune serum as a postexposure therapeutic. Even
though effector functions can enhance protective efficacy of
anti-flavivirus antibodies (Chung et al., 2006; Mehlhop et al.,
2009; Oliphant et al., 2005; Schlesinger et al., 1993), they are
not required for highly neutralizing antibodies. Thus, at least
in mice, even after ADE is initiated, there is a time window in
which neutralizing antibodies that lack the ability to enhance
infection can still protect against lethal disease. These results
are a foundation for further investigation to address whether
antibody-based therapeutics can control severe DENV disease
in humans.EXPERIMENTAL PROCEDURES
Memory B Cell Immortalization and Cloning
Peripheral blood samples were obtained from donors who had been diag-
nosed with DENV infection. The study protocol was approved by the Scientific
and Ethical Committee of the Hospital for Tropical Diseases and the Oxford
Tropical Research Ethical Committee. All provided written informed consent.
The determination of primary or secondary dengue was made on the basis
of acute serology and results of PRNT50 assays in late convalescence.
Peripheral blood mononuclear cells were isolated and cryopreserved. On
the day of use, PBMC were thawed and IgG+ memory B cells were enriched
using CD22 microbeads (Miltenyi) followed by cell sorting as described
(Traggiai et al., 2004). Cells were immortalized at 20 cells/well in multiple
cultures using EBV with CpG oligodeoxynucleotide 2006 (Microsynth) and
irradiated allogeneic PBMC. After 2 weeks, the culture supernatants were
screened for the presence of DENV-specific mAbs, and positive cultures
were cloned by limiting dilution.Intracellular Staining
C6/36 or Vero cells were infected with the DENV-3 recovered from donor 76,
with the DENV-1 recovered from donor 12, with DENV-2 WHO reference strain
516803, or with DENV-1–4 vaccine strains at MOI leading to 70%–90% of
infected cells. After 5 days, cells were harvested, fixed with 2% formaldehyde
(Sigma), and permeabilized in PBS 1% FCS 0.5% saponin (Sigma). Cells were
then incubated for 1 hr on ice with B cell culture supernatants, washed and
stained with Cy5-conjugated goat anti-human IgG (Jackson Immunore-
search), and analyzed on a FACSArray (BD Biosciences).ELISA
96-well ELISA plates were coated at 4C with recombinant E protein from
DENV-1–4 (Rey, 2003), with recombinant DIII from the DENV-3 of donor 76,
or with DIII of DENV-4 (Simonelli et al., 2010) (all at 1 mg/ml in 0.1M Na
carbonate buffer [pH 9.3]). After washing and blocking, mAbs were added
for 1 hr at 37C. After further wash, mAbs bound were revealed using goat
anti-human IgG coupled to alkaline phosphatase (Jackson Immunoresearch).
In some experiments, ELISA plates were coated with the 4G2 (1 mg/ml)
followed by a mixture of DENV-1–4 antigens.evier Inc.
Cell Host & Microbe
Cross-Reactive Human mAbs to Dengue VirusYeast Expression and Staining
Yeast expressing DI/DII and DIII of DENV-2 E protein were generated as previ-
ously described (see Supplementary Experimental Procedures) (Oliphant
et al., 2006; Sukupolvi-Petty et al., 2007). Yeast cells expressing wild-type or
mutant DI/DII or DIII of DENV or WNV (strain New York 1999) E protein were
stained with mAbs on ice for 30 min. The cells were then incubated with
a goat anti-human IgG conjugated to Cy5 (Jackson Immunoresearch) for
30 min on ice and analyzed by flow cytometry.
Immunoblot Analysis
Equal amounts of concentrated supernatant from DENV-3- or DENV-2-
infected or uninfected Vero cells were separated under nonreducing condi-
tions by SDS-PAGE and transferred onto nitrocellulose membranes. Filters
were blocked with 10% dry skim milk and probed with mAbs. Blots were
incubated with horseradish peroxidase-conjugated mouse anti-human IgG,
sheep anti-mouse IgG, or donkey anti-rabbit IgG and developed with ECL
Plus Western Blotting Detection System (GE Healthcare). E protein was
identified using DV55.1, prM protein was identified using the mouse anti-
prM mAb 2H2 (Falconar, 1999), and NS1 protein was identified using a rabbit
anti-NS1 serum (Young et al., 2000). The C protein was identified as a 16 kD
band.
Production of Recombinant IgG and LALA Variants
RNA was isolated with RNeasy kit (QIAGEN) from EBV-immortalized B cell
clones DV82.11, DV87.1, and DV22.3 and cDNA synthesized with M-MLV
reverse transcriptase (Invitrogen). Variable regions of heavy-chain and
light-chain genes were sequenced and cloned by PCR into human Igg1,
Igk, and Igl expression vectors (provided by M. Nussenzweig, Howard
Hughes Medical Institute, The Rockefeller University, New York) using
gene-specific primers and Pfu Turbo (Stratagene) (Tiller et al., 2008). The
vectors contain a murine Ig gene signal peptide sequence and a multiple
cloning site upstream of human Igg1, Igk, and Igl constant regions, with
either wild-type or with leucine-to-alanine mutations at positions CH2 1.3
and 1.2 of Igg1, according to the IMGT unique numbering for C-DOMAIN
(LALA mutant) (Hessell et al., 2007) introduced by site-directed mutagenesis
(GenScript). Equal amounts of heavy- and light-chain vectors were mixed
with an equal amount of polyethylenimine (Sigma), incubated for 15 min,
and added to 80% confluent HEK293T cells (ATCC) in DMEM supple-
mented with 1% Nutridoma (Roche). Antibodies were recovered from
supernatants harvested 3 days after transfection and purified using protein
A affinity chromatography followed by Sephadex 200 size exclusion chro-
matography.
Infection Neutralization and Enhancement
DENV neutralization was measured using a flow-based assay. The day before
the infection, 5000 Vero cells were plated in 96-well flat-bottom plates.
Different dilutions of mAb were mixed with DENV (all at MOI of 0.04) for 1 hr
at 37C and then added to Vero cells. After 3 days, the cells were fixed with
2% formaldehyde, permeabilized in PBS 1% FCS 0.5% saponin, and stained
with 4G2. The cells were incubated with a goat anti-mouse IgG conjugated to
R-phycoerythrin (Southern Biotechnology) and analyzed by flow cytometry.
EC50 values were determined by nonlinear regression analysis. ADE was
measured by a flow assay using K562 cells. mAbs and DENV (MOI of 0.04)
were mixed for 1 hr at 37C and added to 5000 K562/well. After 3 days, cells
were fixed, permeabilized, and stained with 4G2, and the number of infected
cells was determined by flow cytometry as above.
Effect of LALA Antibodies on ADE
Potent enhancing antibodies (0.1 mg/ml) or serum from primary dengue-
infected donors were mixed with an equal volume of LALA cocktail
(DV82.11 = 2 mg/ml; DV87.1 = DV22.3 = 0.2 mg/ml). Attenuated DENV-1–4 virus
strains (MOI of 0.04) and the antibody were mixed, added to K562 cells, and
incubated for 3 days. Cells were stained with 4G2 and analyzed by flow
cytometry as describe above.
Infection of AG129 Mice
129/Svmice lacking the interferon a/b and g receptors (AG129) (van den Broek
et al., 1995) were bred in the University of California, Berkeley Animal Facility.Cell Host &All experimental procedures were preapproved by the University of California
Berkeley Animal Care and Use Committee (ACUC) and were performed
according to the guidelines of the UC Berkeley ACUC. Mice were injected
i.p. with mAb, PBS, or anti-DENV sera in a total volume of 200 ml and then
infected 18–24 hr later with either 105 or 106 pfu of DENV strain D2S10 diluted
in 100 ml volume by intravenous (i.v.) injection into the tail vein. In some exper-
iments, 50 mg of mAbwere transferred tomice i.v. 24 hr postinfection to assess
the therapeutic efficacy of the mAb.
Statistical Analysis
Mortality data were expressed using Kaplan-Meier survival curves, and log
rank analyses were used to determine statistical significance using Prism
(GraphPad software). Viral load values for different tissues were compared
between experimental groups using a two-sample Wilcoxon rank-sum anal-
ysis (Stata v10, College Station, Texas).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and two tables and can be found with this article online at
doi:10.1016/j.chom.2010.08.007.
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